25 September, 2020

Biotech: The Third Wave

India is on the threshold of the third technological revolution—after the industrial and the IT booms—as old-style ventures romance their biotech ambitions

Atul Loke
Biotech: The Third Wave
outlookindia.com
-0001-11-30T00:00:00+05:53
Medchal, a sleepy, sylvan backwater 40 km from Hyderabad, is the sort of idyll often romanticised on celluloid. But Medchal also hides a surreal sophistication—a state-of-the-art lab where white-robed scientists are busy tweaking genes to fashion life-saving drugs.

It's here that Koduru Ishwari Varaprasad, 52, achieved with panache what bigpharma couldn't. In 1997, he and his argonauts created India's first genetically-engineered (GE) hepatitis B vaccine: Shantha Biotech's Shanvac B. It captured 40 per cent of the market and unleashed a price war that four years and more competitors later has resulted in the vaccine being available for Rs 50 per dose!

Shanvac was the first stone that dropped into India's placid biotech waters, setting off ripples that are now waves. Start-ups are mushrooming, with venture funds from banks, financiers and governments. The department of biotechnology (DBT) has announced an ambitious 10-year vision—vaccines for cholera, malaria and TB, biofertilisers, biopesticides, transgenic crops, gene therapy trials against cancer. State...
unsub

THIS ARTICLE IS PRICELESS...

To read this piece, and more such stories in India's most exciting and exacting magazine, plus get access to our 25-year archives goldmine, please subscribe.


More from Rakesh Kalshian


Latest Magazine

September 28, 2020
content

other articles from the issue

articles from the previous issue

Other magazine section